微生物与情绪：抑郁症中创新的生物标志物方法
Microbes and mood: innovative biomarker approaches in depression
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:13.8
分区:医学1区 Top / 生化与分子生物学1区 医学：研究与实验1区 细胞生物学2区
发表日期:2025 Jan
作者:
Miranda Green, Madhukar H Trivedi, Jane A Foster
DOI:
10.1016/j.molmed.2024.09.002
摘要
尽管精神医学领域在生物标志物发现方面取得了一定进展，但我们改善长期预后仍然不足。个体化治疗的匹配仍是临床上的一大挑战。此外，创新治疗的发展在一定程度上受到对影响临床异质性的个体差异背后生物机制理解有限的限制。肠道微生物群已成为从代谢性疾病到癌症等多种疾病研究的热点领域。这些研究的创新推动了转化突破，提供了基于微生物组的创新方法，有望改善患者的治疗效果。本文回顾了微生物组转化研究如何推动精神健康中生物标志物的发现，特别关注抑郁症。
Abstract
Although the field of psychiatry has made gains in biomarker discovery, our ability to change long-term outcomes remains inadequate. Matching individuals to the best treatment for them is a persistent clinical challenge. Moreover, the development of novel treatments has been hampered in part due to a limited understanding of the biological mechanisms underlying individual differences that contribute to clinical heterogeneity. The gut microbiome has become an area of intensive research in conditions ranging from metabolic disorders to cancer. Innovation in these spaces has led to translational breakthroughs, offering novel microbiome-informed approaches that may improve patient outcomes. In this review we examine how translational microbiome research is poised to advance biomarker discovery in mental health, with a focus on depression.